This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teva Pharmaceutical Industries (TEVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
by Kinjel Shah
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
by Zacks Equity Research
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
by Kinjel Shah
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
by Zacks Equity Research
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
by Zacks Equity Research
SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
by Sundeep Ganoria
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
by Zacks Equity Research
TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
by Kinjel Shah
While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
by Zacks Equity Research
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teva Pharmaceutical Industries (TEVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
by Kinjel Shah
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
by Zacks Equity Research
Dr. Reddy's, Sandoz and Teva Pharmaceuticals have been highlighted in this Industry Outlook article.
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
by Zacks Equity Research
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.